Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative colitis (UC), whereas tumor necrosis factor-alpha (TNF-α) inhibitors are primarily reserved for moderate to severe disease that is refractory to conventional treatment or for the first-line treatment of very severe disease. Takeda’s Entyvio, the first cell adhesion molecule (CAM) inhibitor in UC, offers an alternative treatment option, especially for TNF-α-refractory patients. In addition, Pfizer’s Xeljanz is the first Janus kinase (JAK) inhibitor and first oral agent approved (2018) for the treatment of UC. However, these two newer agents are not approved for the treatment of pediatric UC. Given the limited number of therapies available for pediatric patients who fail TNF-α inhibitors, physicians may turn to these agents as a last-line option. Indeed, the availability of these newer agents will likely make the treatment landscape more complex.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric UC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric UC patients?
- What percentage of pediatric UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of pediatric UC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric
- Treatment Algorithm: Claims Data Analysis Pediatric Ulcerative Colitis US February 2019
Author(s): Qinghui Yu, PhD
Qinghui Yu is a business insights analyst at Decision Resources Group. She has authored market research reports analyzing market trends in autoimmune diseases. Prior to joining Decision Resources Group, Dr. Yu worked as a senior analyst for a life science consulting firm, where she worked on a range of projects providing strategic growth advice to clients in life science ;Qinghui Yu holds a in Neuroscience from Columbia University.